TVTX

TVTX EBITDA Growth

105.37%TTM

Period ending:

TVTX TTM EBITDA YoY %%
TVTX TTM EBITDA YoY %16433.79%-146579.30%
2010-05-312026-06-30

Source: Financial Modeling Prep (FMP). Trailing twelve months (TTM). TTM flows use four complete reported quarters. Growth compares with the corresponding period one year earlier.

TVTX ebitda growth history

Year-over-year EBITDA growth rate. The available trailing twelve months (ttm) series contains 65 observations from May 31, 2010 to Jun 30, 2026.

Travere Therapeutics Inc EBITDA Growth — Trailing twelve months (TTM)
Period endingEBITDA Growth
105.3672%
122.9101%
108.3605%
92.3248%
67.2099%
53.2677%
17.9412%
3.094%
-8.1412%
-32.6205%
-29.185%
-27.7742%
-63.6752%
-72.7911%
-88.6123%
-16.9448%
3.2254%
12.5864%
8.4293%
-270.7432%
-171.5946%
-113.8527%
-35.3953%
35.0584%
32.1857%
9.0725%
-42.8655%
-0.8545%
-103.1052%
-111.583%
-94.0576%
-108.1913%
1.0945%
6.8225%
3.034%
41.9975%
1.3828%
1.7345%
25.0104%
-156.0669%
-38.6695%
48.0004%
50.1775%
74.8031%
59.4192%
-105.9445%
-336.7171%
-738.3898%
-1,266.3677%
-2,391.0237%
-58,939.9831%
-130,803.8426%
-53,232.5605%
-13,842.6667%
658.3333%
-30.2409%
-15.26%
-158.3602%
-367.3374%
-875.7143%
-1,226.253%
-492.3628%
119.2422%
92.9156%
88.9021%

Compare ebitda growth

All TVTX financial metrics · TVTX stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.